Tim Lu’s quest to break new cell ther­a­py ground with gene cir­cuits gets Bay­er’s back­ing in a big new fi­nanc­ing round

When Tim Lu spun him­self out of MIT to de­vote some se­ri­ous at­ten­tion to his biotech start­up Sen­ti Bio­sciences more than 3 years ago, it was clear from the be­gin­ning that he was at­tempt­ing to break some com­plete­ly new ground in drug de­vel­op­ment. Mix­ing an aca­d­e­m­ic back­ground that in­clud­ed a Har­vard Med ed­u­ca­tion with a com­put­er sci­ences back­ground at MIT, he had been la­bor­ing on a new ap­proach to pro­gram drugs to op­er­ate in a bet­ter way — us­ing his syn­thet­ic gene cir­cuits to com­mand more se­lec­tive tar­get en­gage­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER